Dr Jay Rajda United States

Founded in 1853 in Hartford, CT, Aetna is committed to providing individuals, employers, health care professionals, producers and others with innovative benefits, products and services. Discover more about our organization.

Aetna Innovation Labs
Medical Director 

Mr Nishant Rastogi United States

In 2008 the Leducq Family Trust established Broadview Ventures, Inc.(Broadview). Broadview’s mission is to accelerate the development of promising technology in cardiovascular and neurovascular disease through targeted investments in and support of early stage ventures.

By making funding available at a critical moment in the development of new technology, the Leducq Family Trust is taking a leadership position in venture philanthropy by finding creative ways to support translational research in order to bring the advancements of science to the care of patients.

Nishant "Nish" Rastogi shares responsibility for the day-to-day operations of Broadview Ventures, including identification and screening of new opportunities, due diligence, negotiation of deal structure, and portfolio company involvement.

Broadview Ventures
Investor 

Dr SATINDER RAWAT United States

UMass at a Glance

UMass Amherst, the Commonwealth's flagship campus, is a nationally ranked public research university offering a full range of undergraduate, graduate and professional degrees.

UMASS
LICENSING OFFICER 

Dr Louai Razzouk United States

NYU Langone Medical Center is one of the nation’s premier academic medical centers. Our trifold mission to serve, teach, and discover is achieved daily through an integrated academic culture devoted to excellence in patient care, education, and research.

Located in the heart of Manhattan, with additional facilities throughout the New York City area, NYU Langone consists of four hospitals:

NYU Langone Medical Center
Physician 

Nell Rebowe United States

Anavex™ Life Sciences Corp. is a clinical stage biopharmaceutical company engaged in the development of novel drug candidates to treat Alzheimer’s, CNS diseases and various types of cancer, which have significant unmet medical needs.

ANAVEX™ 2-73, the Company’s orally available drug candidate developed to treat Alzheimer’s through potential disease modification, has undergone an initial Phase 1 human clinical trial and was well tolerated in doses up to 55mg.  Results from pre-clinical studies indicate that ANAVEX 2-73 demonstrates anti-amnesic and neuroprotective properties.

A highly encouraging synergistic effect has also been observed between ANAVEX 2-73 and donepezil (Aricept®).  The combined therapeutics, referred to as “ANAVEX™ PLUS,” produced up to 80% greater reversal of memory loss in Alzheimer’s disease models versus when the drugs were used individually.

ANAVEX PLUS is believed to be a compelling commercial opportunity.  The clinical trial risk is lower because donepezil (Aricept®) is already on the market, with global sales of $4-billion annually.  Donepezil (Aricept®) is now generic and a patent application has been filed for ANAVEX PLUS which, if granted, would provide protection until 2033.

Headquartered in New York, Anavex is an American publicly traded corporation quoted as AVXL.

Nell Rebowe
Anavex Life Sciences Corp.
Director of Business Development and Investor Relations 

Brendan Reilly United States

Stage1
CTO 

Mr Howard Reis United States

HEALTHePRACTICES (HeP) provides expertise in assisting healthcare practices and technology companies to achieve specific goals toward the delivery of excellent care to their clients. We provide Business Development and Consulting support with a focus on all aspects of telemedicine with a particular interest in medical imaging.

HEALTHePRACTICES
President 

Rahul Remanan United States

Hospital for Special Surgery
Research 

Mrs Stephanie Ressler United States

Ressler
Attorney 

Mr Gilbert Reveillon France

Present in 146 countries, CCEs form an active network of over 4,000 members at the service of French companies around the world.


Selected for their competence and their international experience, the 'Conseillers du Commerce extérieur de la France' (CCE - French Foreign Trade Advisor) are appointed for three years through a prime ministerial decree, on the recommendations of the Minister for Foreign Trade. For more than 115 years, on a voluntary basis, they have been placing their experience at the service of France's economic presence around the world.

CNCCEF - ICT
President ICT & CDO